Search results
Results from the WOW.Com Content Network
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [ 8 ] [ 9 ] Epoetin alfa is an erythropoiesis-stimulating agent. [ 8 ]
The 2020 Cochrane Anaesthesia Review Group review of erythropoietin (EPO) plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non‐cardiac surgery [11] demonstrated that patients were much less likely to require red cell transfusion and in those transfused, the volumes were unchanged (mean ...
Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) in January 2008 to market a continuous erythropoiesis receptor activator (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia in patients with chronic kidney disease, including in those undergoing dialysis.
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
After successful tests on patients undergoing dialysis, Epoetin alfa, marketed by Amgen under the trade name Epogen starting in 1989, became a financial success, generating a billion-dollar market for Amgen and other companies that had developed their own versions of erythropoietin, though Goldwasser would say that "the enormous clinical ...
Methoxy polyethylene glycol-epoetin beta, sold under the brand name Mircera, is a long-acting erythropoietin receptor activator (CERA) used for the treatment of anaemia associated with chronic kidney disease. [4] It is the first approved, chemically modified erythropoiesis-stimulating agent (ESA). [citation needed]
Patients with systemic lupus erythematosus (SLE) who are treated with the standard of care, including biologic response modifiers, experience a higher risk of mortality and opportunistic infection compared to the general population.